

REMARKS

Claims 1-20 are pending in the application. Claims 1, 3, and 4 are amended, claim 2 is cancelled, and claims 5-20 are withdrawn.

Support for the amendment of claims 1-4 can be found throughout the specification and claims as originally filed. For example, support for the amendment of claim 1, which now recites specific polymorphisms of IL-10 (e.g., a G to A substitution at position -1082, a T to C substitution at position -819 and an A to C substitution at position -592), is provided at page 3, first paragraph; support for the amendment of claim 3, which now recites the -174C allele of IL-6, and Apo-E 4 carrier status, is provided, respectively, for example, at page 30, line 30, and at page 24, line 5; and support for the amendment of claim 4, which now recites the -1082A allele of IL-1, is found, for example, at page 24, line 28. No new matter has been added.

CONCLUSION

Applicants believe that no fee is due to consider the present amendment. Nevertheless, the Director is hereby authorized to charge or credit any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105.

Dated: September 11, 2007

Respectfully submitted,

By 

Melissa Hunter-Ensor, Ph.D.

Registration No.: 55,289

EDWARDS ANGELL PALMER & DODGE
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant